Meeting Report
Uncovering and Addressing Implicit Bias in Oncology
Presented by Rose DiMarco,(1) PharmD, BCPS, BCOP, Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC, and Caressa Valdueza,(3) MSN, AGNP-C
From (1)Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; (2)Cincinnati Cancer Advisors, Cincinnati, Ohio; (3)Weill Cornell Medicine, New York, New York
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2023;14(3):195–199 |
https://doi.org/10.6004/jadpro.2023.14.3.3 |
© 2023 Harborside™
ABSTRACT
Implicit bias affects patient care every day, and not just in oncology. It impacts decision-making in already vulnerable populations such as the historically marginalized racial and ethnic groups, the LGBTQI+ population, patients with disabilities, and patients with low socioeconomic status or low health literacy. At JADPRO Live 2022 in Aurora, Colorado, panelists took a deep look at implicit bias and its impact on health inequities. They then discussed best practices for increasing equity and representation in clinical trials, ways to facilitate equitable communication and interactions with patients, and finally shared steps that advanced practitioners can take to minimize the impact of implicit bias.
For access to the full length article, please
sign in.
